Effect of liraglutide on glucose metabolism. Liraglutide (200 mg/kg) was subcutaneously administered once a day for last 4 weeks of HFD-feeding.

<p>(A) body weights during liraglutide treatment (n = 6–7). Open circles, liraglutide-treated <i>Gcg</i>^<i>gfp/+</i> mice on HFD; closed circles, liraglutide-treated <i>Gcg</i>^{<i>gfp/gfp</i>} mice on HFD. **p < 0.01 vs <i>Gcg</i>^<i>gfp/+</i> mice. ^#p < 0.05; ^##p < 0.01 vs. before liraglutide treatment. (B) Blood glucose levels during IPGTT (n = 6–7). Open circles, liraglutide-treated <i>Gcg</i>^<i>gfp/+</i> mice on HFD; closed circles, liraglutide-treated <i>Gcg</i>^{<i>gfp/gfp</i>} mice on HFD. *p < 0.05; ***p < 0.001 vs. <i>Gcg</i>^<i>gfp/+</i> mice. (C) Plasma insulin levels 0 min (white bars) and 15 min (black bars) after i.p. glucose loading (n = 6–7). (D) Insulin contents in pancreata. White bars, liraglutide-treated <i>Gcg</i>^<i>gfp/+</i> mice on HFD; black bars, liraglutide-treated <i>Gcg</i>^{<i>gfp/gfp</i>} mice on HFD (n = 5–7). Data are presented as means ± SEM.